Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 4Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 20INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 2Pancreatic Cancer Non-resectable 1Pancreatic Cancer Metastatic 1Neoplasm Metastasis 1Carcinoma 1Adenocarcinoma 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × folfirinox × Clear all
NCT03941093 2024-11-05

LAPIS

Kyntra Bio

Phase 3 Completed
284 enrolled 14 charts
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT04431258 2024-03-18

PanC-ASAP

Ability Pharmaceuticals SL

Phase 1/2 Completed
150 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04990037 2023-06-29

CAPAFOUR

Cantargia AB

Phase 1 Completed
25 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals

Phase 3 Completed
528 enrolled 11 charts
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡